Celgene Corp. has made its first big foray into CNS by inking a strategic drug discovery and development collaboration with Germany's Evotec AG to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases.
Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort
Evotec has landed a strategic partnership with Celgene worth up to $295m in neurodegeneration drug discovery based on the German CRO's induced pluripotent stem cell platform.
More from Neurological
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.